This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Life Science North America Therapeutics

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Source
Biotechnology Health Care North America Therapeutics

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes.
Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures.
– Hexagon’s interdisciplinary platform combines technological advances and proprietary insights across machine learning, genomics, synthetic biology and automation to systematically discover new chemical compounds linked to known protein targets.
– Hexagon has built a database of microbial genomes that is more than twice the size of all public databases and is adding thousands of additional genomes per month.

Source
Health Care Health Diagnostics North America Personal Health Therapeutics

Xealth Secures $24 Million in Series B Funding to Accelerate Digital Health

– Xealth, the leader in enabling digital health at scale, announced that the company has secured $24 million in Series B funding led by Advocate Aurora Enterprises, a subsidiary of Advocate Aurora Health.
– Seven additional health systems – Banner Health, ChristianaCare, Cone Health, Memorial Hermann, Nebraska Medicine, Novant Health and Stanford Health Care – join existing health system investors Atrium Health, Cleveland Clinic, Froedtert & MCW Health Network, MemorialCare Innovation Fund, Providence and UPMC.
– This brings the company’s total funding to date to $52.6 million.
– Use of digital therapeutics and remote patient monitoring is accelerating as they help fill a necessary role in extending care options for patients.

Source
Health Care Medical North America Therapeutics

IVX Health Secures $100 Million Growth Investment from Great Hill Partners to Accelerate New Market Expansion

– IVX Health announced the completion of a $100m Series F minority investment from Great Hill Partners.
– Great Hill joins IVX Health’s existing investors including Linden Structured Capital, McKesson Ventures, Health Velocity Capital, and Nueterra Capital.
– IVX Health offers an alternative to hospital-based infusion and injection services, transforming the patient experience by providing a superior level of service in a cost-effective, convenient site of care.
– IVX Health was also named to the prestigious Modern Healthcare Best Places to Work list for a third consecutive year. The organization continues to maintain an industry-leading 97 Net Promoter Score from its patient population.
– Evercore served as financial advisor to IVX Health and TripleTree, LLC served as financial advisor to Great Hill.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
Biotechnology Health Care Medical Pharmaceutical Therapeutics Wellness Western Europe

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Source
Biopharma Biotechnology North America Therapeutics

Elevian Raises $40M Series A

– Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, has raised $40m in an oversubscribed Series A round.
– The round was led by Prime Movers Lab.
– Additional investors include Bold Capital, Leslie Ventures, John A Kuelbs Family Office and others.

Source
Biotechnology Medical North America Therapeutics

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

– Allay Therapeutics completed its oversubscribed $60M Series C financing, led by Arboretum Ventures.
– The proceeds from the Series C will advance the Company’s lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay’s platform for ultra-sustained analgesic products.
– Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States.

Source
Biopharma Biotechnology Therapeutics Western Europe

TreeFrog Therapeutics Raises $75M In Series B Financing

– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.

Source
Biotechnology Life Science North America Therapeutics

Via Nova Therapeutics Raises $20M in Series A Financing

– Via Nova Therapeutics is an Oakland, Calif.-based company established to discover and develop therapeutics for acute and subacute viral infections.
– The company closed raised $20m in Series A financing.
Aditum Bio made the investment.
– The new investment will be used to advance the development of four preclinical antiviral programs in-licensed from Novartis.

Source
Health Care Health Diagnostics Medical North America Therapeutics

Blue Note Therapeutics Raises $5.2M in Additional Series A Funding

– Blue Note Therapeutics raised an additional $5.2m in Series A financing, bringing the company’s Series A financing to a total of $31m.
– The financing was provided by Memorial Sloan Kettering Cancer Center (MSK) and Alumni Ventures who joined Series A lead investors JAZZ Venture Partners and Summer VC.
– The additional proceeds will strengthen Blue Note’s capacity to develop evidence-based therapeutics that serve an increasing number of cancer patients.

Source
Biotechnology North America Therapeutics

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Source
Life Science North America Therapeutics

CoRISMA Raises $27M in Series A Funding

– CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
– The round was led by China Grand Pharmaceutical and Healthcare Holdings Limited.
– The company intends to use the funds to accelerate development and expand availability of the CoRISMA cardiac treatment device.

Source
Biotechnology Health Care Medical Neuroscience North America Therapeutics

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing

– Xalud Therapeutics announced that it has raised $30m in a Series C financing.
– Xalud is developing novel non-viral gene therapies to treat pathologic inflammation.
– XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, modified variant of IL-10 with enhanced durability properties over the naturally occurring wild-type cytokine.

Source
Biotechnology Life Science North America Therapeutics

Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Source
Biotechnology Health Care North America Therapeutics

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.

Source
Biotechnology Health Care Life Science North America Therapeutics

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Source
Biotechnology North America Therapeutics

Swing Therapeutics Raises $9M in Seed Funding

– Swing Therapeutics is a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions.
– The company has raised $9m in seed funding led by Jazz Venture Partners.
– The company also announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s digital therapeutic for the management of fibromyalgia.

Source
Biotechnology Manufacturing North America Therapeutics

Debut Biotech Raises $22.6M in Series A Funding

– Debut Biotech is a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes.
– The company raised $22.6m in Series A funding.
– The round was led by Material Impact with participation from Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures, as well as existing investors including KdT Ventures.
– The new capital will be used to commercialize ingredients developed from its proprietary cell-free biomanufacturing platform.

Source
Health Care Medical North America Therapeutics

Advanced Chemotherapy Technologies, Inc. Awarded $4 Million NIH Grant to Pursue Treatment for Locally Advanced Non-resectable Pancreatic Cancer

– Advanced Chemotherapy Technologies has been awarded a Phase IIb Small Business Innovation research grant expected to total $4 million over two years from the National Cancer Institute, part of the National Institutes of Health.
– The grant, in combination with prior financing, supports development of the company’s ACT-IOP-003 local drug delivery system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.
– Pancreatic cancer is a devastating disease with 5-year survival rates of only 10%. New treatment modalities are desperately needed and ACT is developing the ACT-IOP-003 system for the targeted delivery of the FDA-approved chemotherapy treatment gemcitabine.

Source
Information Technology Internet Medical North America Therapeutics

Mahana Therapeutics Raises $61M in Series B Financing

– Mahana Therapeutics, a San Francisco, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing.
– The round was led by JAZZ Venture Partners and Gurnet Point Capital with participation from new and existing investors Main Street Advisors, KKCG and Lux Capital.
– The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS and accelerate development of several digital therapeutics for chronic health conditions.

Source
Biotechnology North America Therapeutics

Visus Therapeutics Raises $20M in Funding

– Visus Therapeutics from Seattle develops innovative ophthalmic therapies to improve vision for people around the world.
– The company raised $20m in funding.
– The round was led by LSP in Amsterdam with participation from Sage Partners of Hong Kong, Johnson & Johnson Innovation -JJDC, Inc. and other inside investors.
– The new investment will be used to advance its clinical and commercial efforts for lead asset BRIMOCHOL under investigation for presbyopia as well as new research and development activities in its drug development pipeline.

Source
Apps Eastern Asia Health Care Information Technology Therapeutics

S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding

– S-Alpha Therapeutics announced the completion of its Series A financing.
– The company raised a total of $8.7M USD (10 Billion KRW) in financing round.
– In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.

Source
Health Care North America Therapeutics

Aardvark Therapeutics Closes $29M Series B Funding

– Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
– The company completed a $29m Series B financing.
– The round was led by Sorrento Therapeutics with participation from existing investors including Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega.
– The funds raised will be deployed to advance the company’s pipeline of programs for metabolic diseases.

Source
Biotechnology Medical Device Therapeutics Western Europe

Eyevensys Raises $12M in a Series B Plus Funding Round

– Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.
Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
– The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. The condition accounts for approximately 90 percent of all AMD-related blindness. Additionally, the company will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.

Source
Biotechnology Life Science North America Therapeutics

Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

– Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing.
– Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune and inflammatory diseases and to further invest in and scale up manufacturing operations in order to support supply for initial clinical studies.

Source
Biotechnology Health Care Medical North America Therapeutics

Rakuten Medical Closes $166M in Series D Funding

– Rakuten Medical from San Mateo is developing and commercializing innovative oncology products for multiple indications.
– The company raised $166m in Series D funding.
– The round was led by General Catalyst with additional participation from existing investors, including Rakuten Group and SBI Group.
– The new investment will be used to advance ongoing trials of ASP-1929 in several oncologic indications and research and development of additional pipeline therapies being developed using the Illuminox™ platform.

Source
Biotechnology Therapeutics Western Europe

Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology

– Macomics Ltd has closed a follow-on financing of £4.24m from its 2020 Seed round, bringing the total amount raised to £7.44m.
– The additional investment brings in new investor Caribou Property Limited alongside existing investors Epidarex Capital, who led the round, and Scottish Enterprise.
– It will be used to accelerate the company’s growth, including expansion of the team.
– Macomics is developing precision medicines to modulate macrophages for the treatment of cancer.
– The company was co-founded in 2019 by Prof Jeffrey Pollard and Dr Luca Cassetta, University of Edinburgh, internationally recognised leaders in macrophage biology.
– It is progressing a diversified portfolio of therapies targeting disease specific tumour associated macrophages (‘TAMs’) towards the clinic.

Source
Health Care mHealth North America Therapeutics Wellness

SonderMind Raises $150M in Series C Funding

– SonderMind Inc. from Denver, CO develops behavioral health technology to improve mental health clinical outcomes.
– Company closed $150m Series C financing.
– The round was co-led by new investors Drive Capital and Premji Invest with participation from General Catalyst, Partners Group, Smash Ventures, Kickstart Fund, F-Prime Capital, Founders Circle Capital, Zoma Foundation and FCA Venture Partners.
– The new investment will be used to accelerate the company’s expansion into all 50 states.

Source
Artificial Intelligence Biotechnology Genetics North America Therapeutics

Deep Genomics Raises $180M in Series C Financing

– Deep Genomics announced the closing of a $180m Series C financing round.
– The round was led by SoftBank Vision Fund 2 and includes participation from new investors, Canadian Pension Plan Investment Board, Fidelity Management & Research Company, Alexandria Venture Investments, and existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures.
– Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases.
– The company has leveraged its strategic geographical advantage by combining its teams in Toronto, the birthplace of deep learning and the fastest growing technology hub in North America, with the Boston-Cambridge biotechnology hub, by hiring Jeffrey Brown, PhD, as VP of Preclinical Research, Ferdinand Massari, MD, as Chief Medical Officer, and Amanda Kay, PhD, as Chief Business Officer.

Source
Biotechnology Health Care Music North America Therapeutics

MedRhythms Closes $25M Series B Funding Led by Morningside Ventures and Advantage Capital to Advance Digital Therapeutics Platform

– MedRhythms announced the closing of a $25m Series B financing round co-led by Morningside Ventures and Advantage Capital, with participation from existing investor Werth Family Investment Associates.
– The proceeds from the Series B financing will enable MedRhythms to expand its team and key corporate functions as the company commercializes its flagship product for chronic stroke survivors with walking deficits and advances its digital therapeutics pipeline.

Source
Health Care North America Pharmaceutical Therapeutics

Surface Ophthalmics Raises $25M in Funding

-Surface Ophthalmics, a Pleasanton CA-based pharmaceutical company, raised $25M in funding.
– The round was led by both new and existing investors made up of institutional, healthcare-focused, and other accredited investors, including members of the Surface Board of Directors.
– The company intends to use the funds to advance its clinical programs in ocular diseases.

Source
Biotechnology Medical North America Therapeutics

Slingshot Biosciences Announces $23 Million in Series A Financing

– Slingshot Biosciences closed a $23m Series A financing.
– The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital.
– The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies.
– Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors.
– Slingshot will also invest heavily in its broader adoptive cell therapy and therapeutics platform with this growth financing.
– Cell-derived products comprise the basis of important healthcare technologies worldwide.

Source
Health Care mHealth Personal Health Therapeutics Wellness Western Europe

Employee mental health platform Oliva raises $2.2M pre-seed round led by Moonfire Ventures

– Oliva, a mental health startup, raised $2.2m in pre-seed funding.
– The round was led by Moonfire Ventures, the new seed-stage VC firm from Atomico co-founder Mattias Ljungman.
– Other investors include tech executives from Amazon, Booking.com, DogBuddy, Typeform, Hotjar, TravelPerk and more.

Source
Biotechnology Innovation Management North America Therapeutics

Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Source
Artificial Intelligence Health Care North America Therapeutics

Woebot Health Raises $90M in Series B Funding

– Woebot Health from San Francisco, CA develops relational technologies for mental health.
– Company raised $90m in Series B funding.
– The round was led by existing investor Jazz Venture Partners and Temasek with participation from funds and accounts managed by BlackRock Private Equity Partners and Owl Ventures, Mirae Asset Capital, Kicker Ventures, Alumni Ventures and Gaingels as well as existing investors NEA and AI Fund.
– The new investment will be used to accelerate further development of its relational platform and technologies, advance its lead digital therapeutic candidates, and expand its team and go-to-market activities.

Source
Biotechnology Medical Therapeutics Western Europe

PEP-Therapy Raises €2.6M in Series A Extension Financing

– PEP-Therapy, a biotechnology company based in Paris, raised €3m in Series A funding.
– The funding was led by Anaxago, i&i Prague and BADGE as well as a €1m loan from Bpifrance.
– The company intends to use the funds to finance the Phase I a/b clinical trial of PEP-010, its lead candidate, for the treatment of advanced solid tumors.

Source
Biotechnology Health Care North America Therapeutics

PAQ Therapeutics Raises $30M in Series A Funding

– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.

Source
Biotechnology Health Care Medical Device Therapeutics Western Europe

Dopavision Raises €12M in Series A Funding

– Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
– The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
– The new investment will be used for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications.

Source
Biotechnology North America Therapeutics

Modulus, a cell therapy biotech incubated at the Allen Institute for AI, raises $3.5M

– Modulus Therapeutics, a Seattle-based cellular therapy company, raised $3.5m in seed funding.
– The company combines laboratory research with machine learning to engineer immune cells with enhanced anti-tumor powers.
– Modulus focuses on generating performance-enhancing genetic changes in natural killer (NK) cells, an up-and-coming immune cell type in the cell therapy field.
– The company is building a platform that could potentially provide early cell product candidates to more mature cellular therapy companies for further testing.

Source
Biotechnology North America Therapeutics

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.

Source
Biotechnology North America Therapeutics

Stemson Therapeutics Raises $15M in Series A Funding

– Stemson Therapeutics, a San Diego-based company, closed a $15m Series A financing.
– The round was led by DCVC Bio with participation from Genoa Ventures, AbbVie Ventures and other investors.
– The company intends to use the funds to advance development of its proprietary therapeutic solution to cure hair loss.

Source
Biotechnology Health Care Medical Device North America Therapeutics

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

Source
Clinical Trials Health Care Medical Pharmaceutical Software Therapeutics Western Europe

Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives

– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.

Source
Biotechnology Life Science North America Therapeutics

MOBILion Systems Raises $60M in Series C Funding

– MOBILion System from Chadds Fords develops high-resolution instrumentation for biomarker discovery.
– The company raised $60M in Series C funding.
– The round was led by D1 Capital Partners with participation from aMoon, Agilent Technologies, IP Group, Hostplus and Cultivation Capital.
– The new investment will be used to scale the commercialization of MOBIE® and advance product development for expansion into bioprocessing and multiomic biomarker discovery markets.

Source
Alternative Medicine Biotechnology Health Care North America Therapeutics

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

– Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
– The round was led by BVF Partners L.P., with participation from existing investors including RA Capital Management and Atlas Venture.
Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
– In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology.

Source
Biotechnology Medical Therapeutics Western Europe

Theolytics Expands Series A Funding Round

– Theolytics, an Oxford, UK-based developer of a library of potential adenovirus product candidates and breakthrough bioselection systems, raised new funding from M Ventures.
– Funding was joined by Epidarex Capital and Taiho Ventures in an extension to the Series A financing.
– The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company’s technology platforms.

Source
Health Care Medical North America Personal Health Therapeutics Wellness

Sword Health Raises $85M in Series C Funding

– Sword Health, a New York-based virtual musculoskeletal care provider, raised $85M in Series C funding.
– The round was led by General Catalyst with participation from Bond, Highmark Ventures, and BPEA, along with returning investors Khosla Ventures, Founders Fund, Transformation Capital, and Green Innovations.
– The company intends to use the funds to build the MSK platform that leverages its virtual physical therapy program to drive cost savings to payors, employers and providers.

Source
Biotechnology Genetics Health Care Market Research North America Therapeutics

Apton Biosystems Raises $24M in Series A Financing

– Apton Biosystems, Inc. from Pleasanton, CA develops Super-Res sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing.
– The company closed a $24m Series A financing.
– The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures.
– The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems.

Source
Health Care Hospital North America Therapeutics

Cortica Raises $60M in Series C Funding

– Cortica from San Diego CA is focused on clinical services for autism and other neurodevelopmental conditions.
– Series C $60m funding round was led by Longitude Capital with participation from 406 Ventures, Adam Boehler, Questa Capital and Aperture Venture Partners and Silicon Valley Bank.
– The new financing will be used to accelerate growth, expand centers across multiple states, and investigate novel drug, device, and diagnostic technologies through sponsored and NIH-funded research.

Source
Biotechnology Eastern Asia Health Care Therapeutics

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer

– Orum Therapeutics closed a $84m Series B financing.
– The financing was led by IMM Investment and joined by new investors (KDB Investment and Atinum, among others) and existing investors (Intervest and KB Investment, among others).
– Orum plans to use the proceeds to advance the Company’s lead therapeutic candidates into clinical trials, explore additional payload chemistries to develop additional payloads that modulate the ubiquitin pathway, and other general corporate purposes.
– The company has developed a new class of ADC payloads, called neoDegraders, to specifically degrade intracellular target proteins within cancer cells via the E3 ubiquitin ligase pathway.

Source
Biotechnology Medical North America Therapeutics

Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

– Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies that follow an autologous and universal hypoimmunogenic approach, announced the completion of an oversubscribed $32 million Series A.
– The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.
– Vita’s lead therapy, VTA-100, is currently undergoing investigational new drug (IND)-enabling studies for the treatment of limb-girdle muscular dystrophy (LGMD) 2A/R1. It is designed to be an autologous treatment that combines gene correction and induced pluripotent stem cell (iPSC) technology to help repair and replace muscle cells.

Source
Biotechnology North America Pharmaceutical Therapeutics

Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

– Glycomine, Inc. closed a $68m Series B financing.
– The proceeds of the financing will be used to advance Glycomine’s lead drug candidate, GLM101, through initial clinical trials in patients.
– GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
– The Series B financing includes $35m of new funds in addition to the $33m announced in August 2019.
– Today’s financing was led by new investors, Abingworth and Sanofi Ventures, and joined by RiverVest Venture Partners and Remiges Ventures.

Source
Biotechnology North America Therapeutics

ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics

– ImmuneID, Inc. has raised $50m in Series A financing.
– The round was led by new investor Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management.
– All existing investors participated in the financing, including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.
– Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.

Source
Biotechnology North America Pharmaceutical Therapeutics

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

– Enveda Biosciences announced an oversubscribed $51M Series A funding round.
– The financing was led by Lux Capital with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs along with existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion.
– Nature is the greatest source of therapeutics we know, yet 95 percent of the natural world is a chemical mystery. Enveda is systematically exploring this unknown space to unlock its potential for new medicines with the first high-resolution chemical map of the natural world.
– This new investment will further power Enveda’s data-driven approach to screening, validating, and developing high-potential natural compounds into first-in-class clinical candidates.

Source
Biotechnology Diabetes Health Care Medical North America Therapeutics

ViaCyte Raises $45M in Funding

– ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding.
– The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.
– The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes.

Source
Biotechnology Medical North America Therapeutics

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer

– PanTher Therapeutics announced that it has closed an oversubscribed $5.4M Series A round led by Catalyst Health Ventures, with participation by Angel Physicians Fund and other notable investors.
– The Series A round brings the total amount raised by the company to $7.4M.
– Proceeds from the funding will go toward the company’s first-in-human clinical trial.
– The company also announced the additions of Darshana Zaveri, Managing Partner at CHV, Manish Bhandari, Managing Partner at APF, and Maria Palasis, President and CEO of Lyra Therapeutics, to its board of directors.

Source
Biotechnology Clinical Trials Health Care North America Therapeutics

Circle Pharma Raises $66M in Series C Financing

– Circle Pharma from South San Francisco develops macrocycle drug discovery and development company focused on intractable cancer targets.
– The company raised $66m in Series C financing.
– The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company.
– The new investment will be used to advance its wholly owned cyclin-targeted programs towards the clinic.

Source
Biotechnology Health Care Medical Therapeutics Western Europe

Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development

– Apollo Therapeutics completed a $145m financing round.
– The round was led by Patient Square Capital and included participation from Rock Springs Capital, Reimagined Ventures and UCL Technology Fund.
– Apollo is a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries.
– Apollo is set-up to bridge the gap from deep academic science to patient benefit in the most capital and time efficient way possible.
– Apollo seeks to develop therapeutics that have transformative potential above the current standard of care.

Source
Biotechnology Medical North America Pharmaceutical Therapeutics

Veralox Therapeutics Closes $16.6M Series A Financing

– Veralox is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
– The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO.
– The new investment will be used to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

Source
1 2 3
Crunchbase icon

Content report

The following text will be sent to our editors: